Immuron FY26 Preliminary Results: Record A$7.7M Sales, Loss Narrows 26%, Cash at A$9.0M
IMRN sits 71% above its 52-week low of $0.677 on light trading volume (0.1× avg).
Summary
Immuron reported FY26 preliminary results with record A$7.7M sales (+6%), a 26% narrower net loss, and cash up to A$9.0M. The company issued 88.9M new shares during the year and guided cash runway through FY28.
Key Events · Earnings and Guidance · IMRN
-
Record FY26 Sales of A$7.7M
Revenue grew 5.9% to A$7,713,601, driven by 10% growth in Australia and 7% growth in the U.S. (13% in USD). Gross margin held at 64.5%.
-
Net Loss Narrows 26.4%
Loss after tax improved to A$3,838,699 from A$5,215,987, helped by a 46% reduction in R&D spend to A$1.93M and stable operating expenses.
-
Cash Position Triples to A$9.0M
Cash and equivalents rose from A$2.83M to A$9.02M, driven by A$7.15M in gross proceeds from ATM share issuances during FY26.
-
88.9M New Shares Issued via ATM
Share count increased from 233.96M to 322.85M shares during FY26, with 88.89M shares issued through the At-The-Market facility at prices ranging from US$1.88 to US$2.30.
Analysis · IMRN · Life Sciences
Immuron's first formal preliminary final report confirms the unaudited figures released in July and adds critical new detail: the net loss narrowed 26.4% to A$3.8 million, cash more than tripled to A$9.0 million, and the company issued 88.9 million new shares during FY26 via its ATM facility — a significant dilution event. The FY27 outlook provides a concrete runway through FY28, which removes near-term liquidity risk. For a micro-cap with a market cap under US$9 million, the combination of improving profitability, a strengthened balance sheet, and explicit cash runway guidance is material.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMRN was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $0.68 to $2.39. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.